Literature DB >> 22931362

Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk.

Helen E Chick1, Ali Nowrouzi, Raffaele Fronza, Robert A McDonald, Nicole M Kane, Raul Alba, Christian Delles, William C Sessa, Manfred Schmidt, Adrian J Thrasher, Andrew H Baker.   

Abstract

We have previously shown that injury-induced neointima formation was rescued by adenoviral-Nogo-B gene delivery. Integrase-competent lentiviral vectors (ICLV) are efficient at gene delivery to vascular cells but present a risk of insertional mutagenesis. Conversely, integrase-deficient lentiviral vectors (IDLV) offer additional benefits through reduced mutagenesis risk, but this has not been evaluated in the context of vascular gene transfer. Here, we have investigated the performance and genetic safety of both counterparts in primary human vascular smooth muscle cells (VSMC) and compared gene transfer efficiency and assessed the genotoxic potential of ICLVs and IDLVs based on their integration frequency and insertional profile in the human genome. Expression of enhanced green fluorescent protein (eGFP) mediated by IDLVs (IDLV-eGFP) demonstrated efficient transgene expression in VSMCs. IDLV gene transfer of Nogo-B mediated efficient overexpression of Nogo-B in VSMCs, leading to phenotypic effects on VSMC migration and proliferation, similar to its ICLV version and unlike its eGFP control and uninfected VSMCs. Large-scale integration site analyses in VSMCs indicated that IDLV-mediated gene transfer gave rise to a very low frequency of genomic integration compared to ICLVs, revealing a close-to-random genomic distribution in VSMCs. This study demonstrates for the first time the potential of IDLVs for safe and efficient vascular gene transfer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22931362      PMCID: PMC3523254          DOI: 10.1089/hum.2012.042

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  90 in total

1.  High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR).

Authors:  Manfred Schmidt; Kerstin Schwarzwaelder; Cynthia Bartholomae; Karim Zaoui; Claudia Ball; Ingo Pilz; Sandra Braun; Hanno Glimm; Christof von Kalle
Journal:  Nat Methods       Date:  2007-12       Impact factor: 28.547

2.  Identification of Nogo as a novel indicator of heart failure.

Authors:  Tara A Bullard; Tricia L Protack; Frédérick Aguilar; Suveer Bagwe; H Todd Massey; Burns C Blaxall
Journal:  Physiol Genomics       Date:  2007-10-30       Impact factor: 3.107

Review 3.  Novel vectors for in vivo gene delivery to vascular tissue.

Authors:  Kathryn White; Stuart A Nicklin; Andrew H Baker
Journal:  Expert Opin Biol Ther       Date:  2007-06       Impact factor: 4.388

4.  Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression.

Authors:  S M K Buckley; S J Howe; V Sheard; N J Ward; C Coutelle; A J Thrasher; S N Waddington; T R McKay
Journal:  Gene Ther       Date:  2008-04-24       Impact factor: 5.250

Review 5.  Cell autonomous function of Nogo and reticulons: The emerging story at the endoplasmic reticulum.

Authors:  Felicia Yu Hsuan Teng; Bor Luen Tang
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

6.  Stable gene transfer to muscle using non-integrating lentiviral vectors.

Authors:  Luis Apolonia; Simon N Waddington; Carolina Fernandes; Natalie J Ward; Gerben Bouma; Michael P Blundell; Adrian J Thrasher; Mary K Collins; Nicola J Philpott
Journal:  Mol Ther       Date:  2007-08-14       Impact factor: 11.454

7.  Regulation of Nogo-B expression in the lesion of aortic aneurysms.

Authors:  Jing-Wei Pan; Meng Wei; Peng-Yuan Yang; Xing Zheng; Jing-bo Li; Zhi-gang Lu; Xian-Xian Zhao; Hong Wu; Hui Kang; Yao-cheng Rui
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-09       Impact factor: 2.557

8.  Low levels of Nogo-B in human carotid atherosclerotic plaques are associated with an atheromatous phenotype, restenosis, and stenosis severity.

Authors:  Juan A Rodriguez-Feo; Willem E Hellings; Bart A N Verhoeven; Frans L Moll; Dominique P V de Kleijn; Jay Prendergast; Yuan Gao; Yolanda van der Graaf; George Tellides; William C Sessa; Gerard Pasterkamp
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-04-05       Impact factor: 8.311

Review 9.  Current status of cardiovascular gene therapy.

Authors:  Tuomas T Rissanen; Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2007-05-08       Impact factor: 11.454

10.  Real-time definition of non-randomness in the distribution of genomic events.

Authors:  Ulrich Abel; Annette Deichmann; Cynthia Bartholomae; Kerstin Schwarzwaelder; Hanno Glimm; Steven Howe; Adrian Thrasher; Alexandrine Garrigue; Salima Hacein-Bey-Abina; Marina Cavazzana-Calvo; Alain Fischer; Dirk Jaeger; Christof von Kalle; Manfred Schmidt
Journal:  PLoS One       Date:  2007-06-27       Impact factor: 3.240

View more
  10 in total

1.  Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease.

Authors:  Ngoc B Lu-Nguyen; Martin Broadstock; Maximilian G Schliesser; Cynthia C Bartholomae; Christof von Kalle; Manfred Schmidt; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther       Date:  2014-04-15       Impact factor: 5.695

2.  Integrated analysis of tRNA-derived small RNAs in proliferative human aortic smooth muscle cells.

Authors:  Jian-Zhi Zhao; Qi-Yao Li; Jia-Jie Lin; Li-Yun Yang; Mei-Yang Du; Yu Wang; Ke-Xin Liu; Ze-An Jiang; Huan-Huan Li; Si-Fan Wang; Bo Sun; Shi-Qing Mu; Bin Li; Kun Liu; Miao Gong; Shao-Guang Sun
Journal:  Cell Mol Biol Lett       Date:  2022-06-15       Impact factor: 8.702

3.  Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice.

Authors:  Thipparat Suwanmanee; Genlin Hu; Tong Gui; Cynthia C Bartholomae; Ina Kutschera; Christof von Kalle; Manfred Schmidt; Paul E Monahan; Tal Kafri
Journal:  Mol Ther       Date:  2013-08-14       Impact factor: 11.454

4.  Nogo-B protects mice against lipopolysaccharide-induced acute lung injury.

Authors:  Wujian Xu; Ying Zhu; Yunye Ning; Yuchao Dong; Haidong Huang; Wei Zhang; Qinying Sun; Qiang Li
Journal:  Sci Rep       Date:  2015-07-15       Impact factor: 4.379

Review 5.  The inflammatory protein Pentraxin 3 in cardiovascular disease.

Authors:  Francesco Fornai; Albino Carrizzo; Maurizio Forte; Mariateresa Ambrosio; Antonio Damato; Michela Ferrucci; Francesca Biagioni; Carla Busceti; Annibale A Puca; Carmine Vecchione
Journal:  Immun Ageing       Date:  2016-08-24       Impact factor: 6.400

6.  Hit and go CAS9 delivered through a lentiviral based self-limiting circuit.

Authors:  Gianluca Petris; Antonio Casini; Claudia Montagna; Francesca Lorenzin; Davide Prandi; Alessandro Romanel; Jacopo Zasso; Luciano Conti; Francesca Demichelis; Anna Cereseto
Journal:  Nat Commun       Date:  2017-05-22       Impact factor: 14.919

7.  VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9.

Authors:  Claudia Montagna; Gianluca Petris; Antonio Casini; Giulia Maule; Gian Marco Franceschini; Ilaria Zanella; Luciano Conti; Francesca Arnoldi; Oscar R Burrone; Lorena Zentilin; Serena Zacchigna; Mauro Giacca; Anna Cereseto
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-11       Impact factor: 8.886

8.  Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.

Authors:  Peirong Hu; Yedda Li; Mark S Sands; Thomas McCown; Tal Kafri
Journal:  Mol Ther Methods Clin Dev       Date:  2015-07-22       Impact factor: 6.698

9.  Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles.

Authors:  Anne Prel; Vincent Caval; Régis Gayon; Philippe Ravassard; Christine Duthoit; Emmanuel Payen; Leila Maouche-Chretien; Alison Creneguy; Tuan Huy Nguyen; Nicolas Martin; Eric Piver; Raphaël Sevrain; Lucille Lamouroux; Philippe Leboulch; Frédéric Deschaseaux; Pascale Bouillé; Luc Sensébé; Jean-Christophe Pagès
Journal:  Mol Ther Methods Clin Dev       Date:  2015-10-21       Impact factor: 6.698

Review 10.  Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.

Authors:  Sandro Matosevic
Journal:  J Immunol Res       Date:  2018-09-17       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.